PCSK9 and atherosclerosis: Given that enhanced circulating levels of LDL-C are crucial not only for the development and the progression but also for the outcomes of atherosclerotic CV disease [5], therapies including PCSK9 inhibitors are expected to slow the progression of atherosclerosis and reduce CV events and death.